No. 19
The Verateca TablePeriodic Table of Supplements

Vitamin K2

Vitamin K2 is the name for menaquinones, a group of forms of vitamin K made mostly by bacteria. MK-4, MK-7 and MK-9 are the most studied; supplements contain MK-4 or MK-7. Natto, a Japanese food of fermented soybeans, has high amounts of MK-7. Vitamin K1, phylloquinone from green plants, is the main form of vitamin K in food.

Terms and sources
menaquinones
They share one ring structure and differ in the length of a side chain, from MK-4 to MK-13. NIH Office of Dietary Supplements.
Vitamin K1
This page covers vitamin K2. Amounts and cautions from NIH apply to vitamin K as a whole. NIH Office of Dietary Supplements.

Vitamin K2 in the body

Vitamin K is needed for the normal function of proteins that take part in blood clotting. Vitamin K-dependent proteins are also found in bone and in blood vessel walls.

Terms and sources
needed for the normal function
It is a coenzyme of an enzyme (a carboxylase) that activates these proteins. NIH Office of Dietary Supplements.
bone and in blood vessel walls
Osteocalcin in bone and matrix Gla protein in vessel walls, bone and cartilage. NIH Office of Dietary Supplements.

The body stores little vitamin K and reuses it many times in a recycling loop. Vitamin K is broken down and excreted quickly, so blood levels are low.

Terms and sources
recycling loop
Called the vitamin K-epoxide cycle. Linus Pauling Institute.
excreted quickly
NIH Office of Dietary Supplements. Based on vitamin K1 measurements, the body keeps about 30–40% of a usual oral amount.

Bacteria in the large bowel make menaquinones, mostly long-chain forms. How much of these the body absorbs is unclear. MK-4 is different: the body makes it from vitamin K1 without bacteria.

Terms and sources
large bowel
NIH Office of Dietary Supplements.
unclear
NIH Office of Dietary Supplements. The Linus Pauling Institute adds that vitamin K is absorbed in the small intestine with bile salts. Most bacterial production is in the colon.
makes it from vitamin K1
NIH Office of Dietary Supplements. The Linus Pauling Institute notes that MK-4 is the only menaquinone not made by bacteria.

NIH notes that no data on normal blood ranges of menaquinones are available. Many trials below measure ucOC or dp-ucMGP: inactive forms of vitamin K-dependent proteins.

Terms and sources
NIH notes
NIH Office of Dietary Supplements, Vitamin K fact sheet for health professionals. Vitamin K status is not routinely tested.
ucOC or dp-ucMGP
Undercarboxylated osteocalcin and desphospho-uncarboxylated matrix Gla protein. Trial reports use them as markers of vitamin K status. Lower values mean more of the protein was activated. Lithgow et al., 2026.

Where vitamin K2 comes from

Natto, fermented soybeans, has high amounts of MK-7: 850 mcg in 3 ounces. Cheese and other fermented foods also contain menaquinones; the forms and amounts vary.

Terms and sources
850 mcg in 3 ounces
NIH Office of Dietary Supplements, table of food sources: 708% of the Daily Value. The Linus Pauling Institute gives 998 mcg of MK-7 per 100 g of natto.
vary
They depend on the bacteria used and the fermentation conditions. NIH Office of Dietary Supplements. Some cheeses contain MK-8 and MK-9 (Linus Pauling Institute).

Meat, eggs and dairy foods contain small amounts of MK-4. Poultry and pork contain MK-4 if menadione is added to animal feed.

Terms and sources
small amounts of MK-4
NIH table: 3 ounces of rotisserie chicken breast has 13 mcg. 1 large egg has 4 mcg, and 1 cup of 2% milk 1 mcg.
menadione
A synthetic form of vitamin K (K3) used in feed; animals turn it into MK-4. NIH Office of Dietary Supplements.

Food tables have little data on menaquinones, so intake from them is hard to estimate.

Terms and sources
Food tables
NIH Office of Dietary Supplements; Linus Pauling Institute. Most food values are for vitamin K1.

Supplements contain vitamin K2 as MK-4 or MK-7. Most multivitamins contain vitamin K, typically below 75% of the Daily Value. Products with vitamin K alone or with calcium, magnesium or vitamin D vary more; some list 4,050 mcg.

Terms and sources
MK-4 or MK-7
NIH Office of Dietary Supplements. Vitamin K1 is used as phylloquinone or phytonadione, a synthetic form of K1.
75% of the Daily Value
NIH Office of Dietary Supplements. The Daily Value is 120 mcg.
4,050 mcg
3,375% of the US Daily Value, calculated at 120 mcg. Source: NIH Office of Dietary Supplements.

Daily amounts and the upper limit

NIH notes: "Vitamin K does not have a Tolerable Upper Intake Level because it has a low potential for toxicity." NIH adds: "The FNB did not establish ULs for vitamin K because of its low potential for toxicity." NIH quotes the National Academies' board: "no adverse effects associated with vitamin K consumption from food or supplements have been reported in humans or animals."

Terms and sources
NIH notes
NIH Office of Dietary Supplements, Vitamin K fact sheet for health professionals, section on health risks from excessive vitamin K. A Tolerable Upper Intake Level is a US upper limit.
FNB
The Food and Nutrition Board of the National Academies. ULs are Tolerable Upper Intake Levels. NIH Office of Dietary Supplements.
the National Academies' board
The Food and Nutrition Board, in its 2001 report. NIH Office of Dietary Supplements.

NIH summarizes: "Vitamin K can interact with certain medications, such as warfarin and other anticoagulants. Other medications, including antibiotics, bile acid sequestrants, and orlistat, can have adverse effects on vitamin K levels." NIH notes: "Vitamin K interacts with a few medications. In addition, certain medications can have an adverse effect on vitamin K levels." NIH adds: "Individuals taking these and other medications on a regular basis should discuss their vitamin K status with their health care providers."

Terms and sources
NIH summarizes
NIH Office of Dietary Supplements, Vitamin K fact sheet: summary at the start of the section on interactions with medications.
NIH notes
NIH Office of Dietary Supplements, Vitamin K fact sheet for health professionals, section on interactions with medications.

On warfarin and similar medicines, NIH notes: "Vitamin K can have a serious and potentially dangerous interaction with anticoagulants such as warfarin (Coumadin) as well as phenprocoumon, acenocoumarol, and tioclomarol, which are commonly used in some European countries." NIH adds: "These drugs antagonize the activity of vitamin K, leading to the depletion of vitamin K-dependent clotting factors. People who are taking warfarin and similar anticoagulants need to maintain a consistent intake of vitamin K from food and supplements because sudden changes in vitamin K intakes can increase or decrease the anticoagulant effect."

Terms and sources
NIH notes
NIH Office of Dietary Supplements, Vitamin K fact sheet for health professionals, section on interactions with medications.

About MK-7, the Linus Pauling Institute notes that "therapeutic anticoagulant stability may be undermined by daily doses of MK-7 as low as 10 to 20 μg".

Terms and sources
Linus Pauling Institute
Linus Pauling Institute, Micronutrient Information Center: Vitamin K, section on drug interactions. It refers to people taking warfarin and similar medicines. The same sentence first gives an amount of vitamin K1 for people taking warfarin.

On antibiotics, NIH notes: "Antibiotics can destroy vitamin K-producing bacteria in the gut, potentially decreasing vitamin K status." NIH adds: "This effect might be more pronounced with cephalosporin antibiotics, such as cefoperazone (Cefobid), because these antibiotics might also inhibit the action of vitamin K in the body." It continues: "Vitamin K supplements are usually not needed unless antibiotic use is prolonged (beyond several weeks) and accompanied by poor vitamin K intake."

Terms and sources
NIH notes
NIH Office of Dietary Supplements, Vitamin K fact sheet for health professionals, section on interactions with medications.

On bile acid sequestrants, NIH notes: "Bile acid sequestrants, such as cholestyramine (Questran) and colestipol (Colestid), are used to reduce cholesterol levels by preventing reabsorption of bile acids." NIH adds: "They can also reduce the absorption of vitamin K and other fat-soluble vitamins, although the clinical significance of this effect is not clear." It continues: "Vitamin K status should be monitored in people taking these medications, especially when the drugs are used for many years."

Terms and sources
NIH notes
NIH Office of Dietary Supplements, Vitamin K fact sheet for health professionals, section on interactions with medications.

On orlistat, NIH notes: "Orlistat is a weight-loss drug that is available as both an over-the-counter (Alli) and prescription (Xenical) medication." NIH adds: "It reduces the body's absorption of dietary fat and in doing so, it can also reduce the absorption of fat-soluble vitamins, such as vitamin K. Combining orlistat with warfarin therapy might cause a significant increase in prothrombin time." It continues: "Otherwise, orlistat does not usually have a clinically significant effect on vitamin K status, although clinicians usually recommend that patients taking orlistat take a multivitamin supplement containing vitamin K."

Terms and sources
NIH notes
NIH Office of Dietary Supplements, Vitamin K fact sheet for health professionals, section on interactions with medications.

United States

US recommended amount for adults: 120 mcg of vitamin K a day for men and 90 mcg for women. The Daily Value on US labels is 120 mcg. In a national survey, average intake from food was 138 mcg a day in men and 122 mcg in women.

Terms and sources
recommended amount
Adequate Intake, National Academies, 2001, for ages 19 and over. It was set from vitamin K intakes of healthy people, because data were too limited for an average requirement. It counts food, drinks and supplements together. NIH Office of Dietary Supplements.
Daily Value
Set by the US Food and Drug Administration for adults and children 4 and older. FDA does not require food labels to list vitamin K unless it was added. NIH Office of Dietary Supplements.
national survey
NHANES 2011–2012, adults 20 and over, as summarized by the NIH Office of Dietary Supplements. With supplements: 182 mcg in men and 164 mcg in women. Food tables count mainly vitamin K1.

The National Academies have not set an upper limit for vitamin K. The US Food and Drug Administration has not authorized a health claim for vitamin K.

Terms and sources
upper limit
NIH Office of Dietary Supplements; Linus Pauling Institute.
health claim
NIH Office of Dietary Supplements; Linus Pauling Institute.

Of 321 US labels of vitamin K2-only products, the middle half list 50–150 mcg per serving. The most common amount is 100 mcg. 85% of them name MK-7 and 4% name MK-4; 11% name no form.

Terms and sources
321 US labels
NIH Dietary Supplement Label Database, including products no longer sold. Labels whose only main ingredient is vitamin K2, named as K2, a menaquinone, MK-7 or MK-4. A serving is not always a full day's amount. We counted these.
100 mcg
74 of the 321 labels. Next most often: 90 mcg (52 labels) and 45 mcg (47 labels).
4% name MK-4
12 labels; 3 more name both. MK-4 labels list higher amounts, most often 5,000 mcg (5 of 12). We counted these.

Of 3,782 US labels that list vitamin K2, 83% also list vitamin D, and 50% list calcium.

Terms and sources
3,782 US labels
Labels with at least one vitamin K2 ingredient row, nested or not. Vitamin D and calcium counted as separate main ingredients: 3,123 and 1,890 labels. We counted these.

Forms of vitamin K2 and how they differ

MK-7 has a side chain of 7 units; MK-4 has 4. Supplement MK-4 is also called menatetrenone.

Terms and sources
side chain
Menaquinones are named MK-4 to MK-13 by the length of the side chain. NIH Office of Dietary Supplements.
menatetrenone
Linus Pauling Institute. NIH calls 45 mg of MK-4 "a pharmacological dose" used in Japan and other parts of Asia.

NIH notes that data on the absorption of the different forms of vitamin K in supplements are limited. We do not rank forms.

Terms and sources
NIH notes
NIH Office of Dietary Supplements, Vitamin K fact sheet for health professionals, section on dietary supplements.

Menadione, called vitamin K3, is no longer used in supplements or fortified foods.

Terms and sources
no longer used
Laboratory studies in the 1980s and 1990s found damage to liver cells. NIH Office of Dietary Supplements.
MK-7, MK-4 and other forms of vitamin K
FormVitamin K in the compoundWhat is known
MK-7 (menaquinone-7)100%Vitamin K2 with a long side chain. Natto is rich in it. One study found it well absorbed, with a longer half-life than vitamin K1 (NIH).
MK-4 (menaquinone-4, menatetrenone)100%Vitamin K2 with a short side chain. The body makes it from vitamin K1; meat, eggs and dairy foods contain a little. Not in the NIH summary of absorption by form.
MK-8, MK-9 and longer menaquinones100%Found in some cheeses and in animal livers (Linus Pauling Institute). Not in the NIH summary of absorption by form.
Vitamin K1 (phylloquinone, phytonadione)100%Not vitamin K2. The main form in food, from green leafy vegetables and plant oils (NIH).
Menadione (vitamin K3)100%Synthetic. No longer used in supplements or fortified foods (NIH).

Menaquinones and phylloquinone are themselves vitamin K, so the share is 100%; our calculation. Sources: NIH Office of Dietary Supplements; Linus Pauling Institute.

Published studies of vitamin K2

10 studies from 9 reports: 2 found a difference and 8 had mixed results.

Terms and sources
10 studies from 9 reports
One report describes two separate trials. Doses were 10 mcg to 45 mg a day of MK-7, MK-4 or an unnamed vitamin K2. Measures were bone density, markers of vitamin K status and recovery after exercise.

Studies in healthy adults, each with our one-line summary.

We list the 10 largest studies by number of people randomized. Not listed: studies of people with a diagnosis or selected by a bone scan score, on dialysis, or taking medicines. Also not listed: studies in children and mixes with other nutrients. Also not listed: reviews of studies in people with a diagnosis, and a prevention review. Also not listed: a trial whose random allocation we could not confirm, and studies with doses we could not check. Also not listed: a study without a comparison group, and an analysis of a subgroup selected by a blood marker. Also not listed: second reports of listed trials, and a smaller study beyond the 10 largest.

Our one-line summary comes first. The original is on PubMed.

Show the studies
  • 334 women took 360 mcg MK-7 or dummy capsules for 1 year; ucOC fell; bone loss did not differ.

    Trial · randomized into two groups; the abstract does not give the numbers per group · 1 year · maker-supplied

    Emaus et al., 2010

    Terms and sources
    334 women
    Healthy Norwegian women aged 50–60, 1 to 5 years after menopause. The abstract does not give how many were in each group.
    360 mcg MK-7
    As natto capsules. The dummy capsules looked the same and contained olive oil.
    ucOC fell
    Undercarboxylated osteocalcin fell and carboxylated osteocalcin rose with MK-7 compared with the dummy capsules (p < 0.001).
    bone loss did not differ
    Bone density at the total hip, femoral neck, lumbar spine and whole body after 12 months did not differ significantly. Blood markers of bone formation and breakdown were measured; the abstract reports no difference for them.
    maker-supplied
    Grants from the Norwegian Osteoporosis Association and Northern Norway Regional Health Authorities. NATURAL provided the study capsules. Eckboe's legacy paid for blood analyses.

    Study · Abstract only · about 2 min to read

    Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.

    Study summary

    334 healthy Norwegian women aged 50 to 60 took part, 1 to 5 years after menopause. For 12 months they took 360 mcg of MK-7 a day as natto capsules, or identical olive-oil dummies. Bone density was measured at four sites. Blood markers of bone turnover and osteocalcin were also measured. Bone loss did not differ between the groups at any site. Undercarboxylated osteocalcin fell and carboxylated osteocalcin rose with MK-7. Source: PubMed abstract (PMID 19937427). Funding: grants from the Norwegian Osteoporosis Association and Northern Norway Regional Health Authorities. NATURAL provided the capsules.

  • 325 women took 45 mg MK-4 or dummy capsules for 3 years; hip strength indices differed, bone density did not.

    Trial · randomized: 161 MK-4, 164 dummy capsules; 133 and 124 finished · 3 years · maker-funded

    Knapen et al., 2007

    Terms and sources
    325 women
    Apparently healthy Dutch women aged 55–75, at least 2 years after menopause. Women with low bone density (T-score below −2.5), bone conditions or anticoagulant use were excluded. 161 were assigned MK-4 and 164 dummy capsules.
    45 mg MK-4
    Menatetrenone from Eisai, 3 capsules of 15 mg a day after meals. NIH calls 45 mg of MK-4 "a pharmacological dose" used in Japan and other parts of Asia.
    3 years
    A later report on 164 of these women (Knapen 2012) compared body weight only within each group.
    hip strength indices differed
    Three femoral neck strength indices were significantly higher with MK-4 than with dummy capsules. They are calculated from bone density, neck width and hip axis length. Femoral neck bone mineral content fell less and femoral neck width rose with MK-4. ucOC fell and carboxylated osteocalcin rose. Total osteocalcin and bone-specific alkaline phosphatase were also higher with MK-4. Bone breakdown markers did not differ.
    bone density did not
    No difference in bone density (DXA) at the femoral neck, total hip or lumbar spine. 16 of 161 women with MK-4 and 15 of 164 with dummy capsules reported negative effects. Total complaints did not differ.
    maker-funded
    Eisai supplied the menatetrenone and an unrestricted research fund (Acknowledgement).

    Study · Free full text · about 25 min to read

    Our estimate at about 200 words a minute, from the PMC full text.

    Study summary

    325 apparently healthy Dutch women aged 55 to 75 took part, at least 2 years after menopause. They took 45 mg of MK-4 a day, as three 15 mg capsules, or dummy capsules for 3 years. 161 were assigned MK-4 and 164 dummy capsules. Bone density by DXA did not differ. Femoral neck bone mineral content fell less and femoral neck width rose with MK-4. Three calculated hip strength indices were higher with MK-4. ucOC fell. Side effects were similar. Source: PMC full text (PMID 17287908). Eisai supplied the menatetrenone and an unrestricted research fund.

  • 244 women took 180 mcg MK-7 or dummy capsules for 3 years; bone loss differed at 2 of 3 sites.

    Trial · randomized: 120 MK-7, 124 dummy capsules (from a second report of this trial) · 3 years · industry-funded

    Knapen et al., 2013

    Terms and sources
    244 women
    Healthy Dutch women after menopause. A second report of the same trial (Knapen 2015) gives 120 assigned MK-7 and 124 dummy capsules.
    180 mcg MK-7
    Capsules. The second report names the product MenaQ7.
    3 years
    Second reports of this trial: Knapen 2015 reports that two artery-stiffness measures fell over 3 years with MK-7. Its abstract gives no comparison with dummy capsules for them. In Knapen 2015, dp-ucMGP was 50% lower than with dummy capsules; inflammation markers did not differ. Knapen 2017 found no difference in body composition in the whole group.
    bone loss differed at 2 of 3 sites
    The age-related fall in bone density and content was significantly smaller with MK-7 at the lumbar spine and femoral neck. The total hip did not differ. Calculated bone strength also differed, and loss of vertebral height (lower thoracic spine, mid-site) was smaller with MK-7. The ucOC:cOC ratio fell.
    industry-funded
    Funded by Nattopharma ASA (Acknowledgments). We could not read Methods, so we do not know who made the capsules.

    Study · Abstract only · about 2 min to read

    Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.

    Study summary

    244 healthy Dutch women after menopause took 180 mcg of MK-7 a day or dummy capsules for 3 years. Bone density and content were measured each year at the lumbar spine, total hip and femoral neck. Calculated bone strength, vertebral height and osteocalcin were also measured. The fall in bone density was smaller with MK-7 at the lumbar spine and femoral neck. The total hip did not differ. Calculated bone strength and vertebral height also differed. Source: PubMed abstract (PMID 23525894). Nattopharma ASA funded the study.

  • 311 adults took K2, some with calcium and D, or dummy pills; 90 mcg: women lost less bone, men not.

    Trial · 311 randomized into 4 groups, one of them with calcium and vitamin D; group sizes not in the abstract · 1 year

    Zhang et al., 2020

    Terms and sources
    311 adults
    Men and women after menopause, aged 50–75, living in the community in China. 4 groups: 50 mcg, 90 mcg, 90 mcg with calcium 500 mg and vitamin D 10 mcg, or dummy pills. The abstract does not give group sizes or exclusions.
    K2
    The abstract does not name the form. Doses were 50 or 90 mcg a day.
    women lost less bone
    In women, femoral neck bone loss was significantly lower in both 90 mcg groups than with dummy pills (p = 0.006). One of them also took calcium and vitamin D. The abstract does not report the 50 mcg group on this measure. The ratio of carboxylated to undercarboxylated osteocalcin rose in the vitamin K2 groups.
    men not
    No effect on bone loss in men. Adding calcium and vitamin D to 90 mcg gave no additional effect.

    Study · Abstract only · about 2 min to read

    Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.

    Study summary

    311 men and women after menopause, aged 50 to 75, took part in China. They were randomly assigned to 50 or 90 mcg of vitamin K2 a day, or dummy pills, for 1 year. A fourth group took 90 mcg with calcium and vitamin D. The abstract does not name the form of vitamin K2. In women, femoral neck bone loss was lower in both 90 mcg groups than with dummy pills. Men did not differ. Source: PubMed abstract (PMID 32060566). The paper's Funding section names a Heilongjiang Province research grant.

  • 120 adults aged 20–69 took 100 mcg MK-7 or a dummy product for 12 weeks; ucOC fell.

    Trial · randomized: 60 MK-7, 60 dummy (stratified); 115 analyzed · 12 weeks · industry author

    Inaba et al., J Nutr Sci Vitaminol, 2015

    Terms and sources
    120 adults aged 20–69
    Healthy Japanese men and women not under medical treatment; 60 were allocated to each group. People with abnormal or unstable osteocalcin values at screening were excluded. This is Study 2 of the paper; Study 1, listed below, chose the dose.
    ucOC fell
    Undercarboxylated osteocalcin fell, and the ratio of carboxylated to undercarboxylated osteocalcin rose, significantly more with MK-7 than with the dummy. Clotting time (PT-INR) did not differ between groups. The paper reports no adverse effects linked to the products.
    industry author
    All three authors are from the R&D Division of J-Oil Mills, Inc. The paper states: "This study did not receive any funding."

    Study · Free full text · about 23 min to read

    Free full text on J-STAGE. Our estimate at about 200 words a minute, from the J-STAGE full text.

    Study summary

    This is the second of two trials in this report. 120 Japanese adults aged 20 to 69 took 100 mcg of MK-7 or a dummy product for 12 weeks. Blood carboxylated and undercarboxylated osteocalcin were measured. Undercarboxylated osteocalcin fell with MK-7 compared with the dummy. The ratio of carboxylated to undercarboxylated osteocalcin rose. Source: J-STAGE full text (PMID 26875489). All three authors work at J-Oil Mills, Inc.; the paper reports no funding.

  • 71 adults finished 12 weeks of 240 mcg MK-7 or dummy tablets; blood MK-7 rose, exercise recovery did not differ.

    Trial · 80 enrolled, 75 completed baseline tests, 71 finished; the text we read does not give the number randomized to each group · 12 weeks · maker-funded

    Lithgow et al., Med Sci Sports Exerc, 2026

    Terms and sources
    71 adults
    Healthy adults aged 18–40 and 65+ in Glasgow who did little hard exercise. 35 young and 36 older adults finished. People with listed conditions, smokers and anyone taking vitamin K antagonists were excluded.
    240 mcg MK-7
    One tablet a day with lunch or dinner (K2VITAL). The dummy was a cellulose tablet that looked and tasted the same.
    exercise recovery did not differ
    Strength, sit-to-stand time, soreness and inflammation markers up to 72 hours after exercise: no supplement-by-time differences. Blood MK-7 rose with MK-7. In older adults only, muscle-signal measures (EMD, RMS), creatine kinase and IL-6 differed by group. The authors call these exploratory. Slower sit-to-stand time and less soreness in the MK-7 group were overall group effects, not changes over time. Older adults also had lower dp-ucMGP at 12 weeks with MK-7.
    maker-funded
    Kappa Bioscience AS funded the study and provided the tablets. The paper calls it the manufacturer. It had no role in data collection or analysis.

    Study · Free full text · about 25 min to read

    Our estimate at about 200 words a minute, from the PMC full text.

    Study summary

    Healthy adults aged 18 to 40 and 65 and over took part. They did little resistance exercise. They took 240 mcg of MK-7 or a dummy tablet a day for 12 weeks. 80 enrolled and 71 finished. Before and after, they did one bout of leg and chest exercise. Strength, sit-to-stand time, soreness and blood markers were measured over 72 hours. Recovery did not differ between groups. Blood MK-7 rose. Some measures in older adults differed by group. Source: PMC full text (PMID 41843412). Kappa Bioscience funded the study and provided the tablets.

  • 60 adults took 180 or 360 mcg MK-7 or a dummy product; dp-ucMGP fell, other markers did not differ.

    Trial · randomized to 3 groups; group sizes not in the abstract · 12 weeks

    Dalmeijer et al., 2012

    Terms and sources
    60 adults
    Dutch men and women aged 40–65. The abstract does not state health criteria or group sizes.
    dp-ucMGP fell
    Inactive matrix Gla protein fell by 31% with 180 mcg and 46% with 360 mcg (p < 0.001). It did not change with the dummy. The ucOC:cOC ratio fell by 60% and 74%.
    other markers did not differ
    Two other forms of matrix Gla protein and other risk markers did not differ between the groups.

    Study · Abstract only · about 2 min to read

    Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.

    Study summary

    60 Dutch men and women aged 40 to 65 took part. They took 180 or 360 mcg of MK-7 a day or a dummy product for 12 weeks. Forms of matrix Gla protein, the osteocalcin ratio and other risk markers were measured at 0, 4 and 12 weeks. Inactive matrix Gla protein (dp-ucMGP) fell with both doses. It did not change with the dummy. Two other forms of the protein and other risk markers did not differ. Source: PubMed abstract (PMID 23062766). Europe PMC lists the Netherlands Heart Foundation as the funder.

  • 60 women took MK-7 or a dummy; carboxylation ratio higher at 100–200 mcg; cOC, ucOC levels did not differ.

    Trial · allocated to 4 groups of 15 by stratified randomization; 57 analyzed · 4 weeks · industry author

    Inaba et al., J Nutr Sci Vitaminol, 2015

    Terms and sources
    60 women
    Japanese women aged 50–69 after menopause. They ate a controlled diet with the Japanese recommended vitamin K intake. 15 women were allocated to each dose group: 0, 50, 100 or 200 mcg. This is Study 1 of the paper.
    a dummy
    MK-7 was dissolved in oil and processed into 20 g of mayonnaise (Knorr Foods). The 0 mcg mayonnaise was identical in appearance, texture and taste.
    carboxylation ratio higher at 100–200 mcg
    The ratio of carboxylated to undercarboxylated osteocalcin was measured. Its change from baseline was significantly higher at 100 and 200 mcg than at 0 mcg. The paper reports no significant difference at 50 mcg. In the 0 mcg group, the ratio fell from baseline.
    cOC, ucOC levels did not differ
    Concentrations of carboxylated and undercarboxylated osteocalcin did not differ significantly among the groups. Within groups, ucOC rose from baseline at 0 mcg and fell at 200 mcg. The paper reports no adverse effects linked to the products.
    industry author
    All three authors are from the R&D Division of J-Oil Mills, Inc. The paper states: "This study did not receive any funding." The MK-7 was dissolved in oil from J-Oil Mills.

    Study · Free full text · about 23 min to read

    Free full text on J-STAGE. Our estimate at about 200 words a minute, from the J-STAGE full text.

    Study summary

    This is the first of two trials in this report. 60 Japanese women aged 50 to 69 after menopause ate a controlled diet. They took 0, 50, 100 or 200 mcg of MK-7 a day for 4 weeks. Blood carboxylated and undercarboxylated osteocalcin were measured. Their ratio fell from baseline at 0 mcg. Its change was higher at 100 and 200 mcg than at 0 mcg. Concentrations of the two forms did not differ between groups. Source: J-STAGE full text (PMID 26875489). All three authors work at J-Oil Mills, Inc.; the paper reports no funding.

  • 48 women took 1.5 mg MK-4 or a dummy product for 12 months; ucOC was lower than with the dummy.

    Trial · randomized: 24 MK-4, 24 dummy · 12 months · industry co-funded

    Koitaya et al., J Bone Miner Metab, 2014

    Terms and sources
    48 women
    Japanese women aged 50–65 after menopause; 24 were assigned MK-4 and 24 the dummy. The paper aimed to test healthy women. ucOC was high at the start in both groups.
    ucOC was lower
    Lower with MK-4 than with the dummy at 6 and 12 months. Forearm bone density and pentosidine were compared only within each group. Forearm density fell between 6 and 12 months with the dummy, not with MK-4.
    industry co-funded
    Funded by a grant from Japan's National Institute of Health and Nutrition and by Kyowa Hakko Bio (Acknowledgments). Four authors work at Kyowa Hakko Bio. The authors declare no conflicts of interest. We could not read Methods, so we do not know who made the product.

    Study · Abstract only · about 2 min to read

    Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.

    Study summary

    48 Japanese women aged 50 to 65 after menopause took part. They took 1.5 mg of MK-4 a day or a dummy product for 12 months; 24 were in each group. Bone turnover markers, ucOC, pentosidine and forearm bone density were measured at 0, 6 and 12 months. ucOC was lower with MK-4 than with the dummy at 6 and 12 months. Forearm density was compared only within each group. Source: PubMed abstract (PMID 23702931). Funding: a government institute grant and Kyowa Hakko Bio.

  • 42 adults took 10–360 mcg MK-7 or dummy capsules; carboxylation rose at higher doses; thrombin generation did not change.

    Trial · randomized to 7 groups of 6: dummy capsules or 10, 20, 45, 90, 180 or 360 mcg · 12 weeks · maker-funded

    Theuwissen et al., Br J Nutr, 2012

    Terms and sources
    42 adults
    Healthy Dutch men and women aged 18–45. Seven groups: dummy capsules or 10, 20, 45, 90, 180 or 360 mcg of MK-7. Six people per group, for 12 weeks (Methods).
    carboxylation rose at higher doses
    For statistics, the authors pooled the groups into dummy, doses below and doses around the EU recommended daily amount. Osteocalcin and matrix Gla protein carboxylation rose at doses around that amount. A later report on stored samples (Knapen 2012) found no link between vitamin K status and adiponectin.
    thrombin generation did not change
    Calibrated thrombin generation tests: the abstract reports no adverse effects.
    maker-funded
    Nattopharma ASA funded the study (Acknowledgements). Methods say NattoPharma ASA produced the MenaQ7 capsules, including the dummy capsules. The paper reports no author conflicts of interest.

    Study · Abstract only · about 2 min to read

    Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.

    Study summary

    42 healthy Dutch adults aged 18 to 45 took part. They were randomly assigned to dummy capsules or one of six MK-7 doses, 10 to 360 mcg. Each group had 6 people and took capsules for 12 weeks. Osteocalcin, matrix Gla protein and thrombin generation were measured. With dose groups combined, carboxylation of both proteins rose at doses around the EU recommended amount. Thrombin generation showed no adverse effects. Source: PubMed abstract and the journal page (PMID 22289649). Nattopharma ASA funded the study and produced the capsules.

Sources

Information, not a prescription. Do not start, stop or combine supplements or medicines on your own.